Core Viewpoint - The company plans to acquire 100% equity of Guangzhou Yijie Medical Technology Co., Ltd., which is expected not to constitute a major asset restructuring but will be classified as a related party transaction [1] Group 1: Transaction Details - The transaction was initiated on May 22, 2025, and has gone through various stages including suspension and resumption of trading [1] - As of September 30, the company is cooperating with intermediaries to conduct due diligence, which is still ongoing [1] Group 2: Approval Process - The transaction requires approval from the board of directors and shareholders, as well as review by the Shenzhen Stock Exchange and registration with the China Securities Regulatory Commission [1] - There is uncertainty regarding the completion of the transaction, and the company will disclose updates in a timely manner [1]
迈普医学披露购易介医疗股权交易进展，仍存不确定性